BioSeeker Group AB

BioSeeker Group is a business and competitive intelligence company for investment, venture and R&D management of biotechnology and pharmaceutical companies. It serves the needs of individuals, companies, and institutional clients with a diverse range of information and analysis services.

BioSeeker Group has a strong client focus providing decision-makers, investors, and management people with candid, credible research coverage on biotechnology and pharmaceutical companies. The firm is committed to creating value for clients by providing wisdom and high quality services that meet clients' needs. BioSeeker's clients and projects are kept confidential.

...Show More ...Show Less

15 Reports from BioSeeker Group AB

   
  • Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool

    Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool Targeting the CD47-SIRPα axis is emerging as one of the most promising new cancer immunotherapy approaches seeking to target innate immune response. This report reveals intense global interest and a growing list of stakeholders operating in ... Read More

  • Immuno-Oncology Drug Development: Analytical Tool

    Immuno-Oncology Drug Development: Analytical Tool Immuno-Oncology (I-O) has quickly become to be the 4th pillar of cancer therapy and encompasses a highly diverse portfolio of treatment strategies from the early interferon-α/interleukin-2 therapies to the current progress of immune-checkpoint inhibi ... Read More

  • Bispecific Molecules in Oncology: Analytical Tool

    Bispecific Molecules in Oncology: Analytical Tool Bispecific molecules carry huge treatment potential within cancer immunotherapy. In broad strokes this therapeutic category can be divided into three classes: (I) cytotoxic effector cell redirectors/CTL response; (II) tumor-targeted immunomodulators; ... Read More

  • Epigenetic Therapies in Oncology: Analytical Tool

    Epigenetic Therapies in Oncology: Analytical Tool In cancer, many aspects of the epigenome, controlled by DNA methylation, chromatin, and nucleosome positioning, are altered and an ever growing pipeline of agents targeting epigenetic regulation are under development and entering clinical trials. Epi ... Read More

  • Oncolytic Virotherapies: Analytical Tool

    Oncolytic Virotherapies: Analytical Tool Oncolytic virotherapy is a hot emerging treatment modality were therapeutically useful anticancer viruses will selectively infect and damage cancerous tissues without causing harm to normal tissues. Oncolytic viruses have shown limited clinical efficacy as a ... Read More

  • Cancer Vaccines: Analytical Tool

    Cancer Vaccines: Analytical Tool With the first prophylactic cancer vaccine Gardasil approved in 2006 and therapeutic cancer vaccine Sipuleucel-T (Provenge) approved in 2010, cancer vaccines is a proven hot treatment modality which is now turbocharged with the event of immune-checkpoint inhibitors. ... Read More

  • CAR/TCR Therapies in Oncology: Analytical Tool

    CAR/TCR Therapies in Oncology: Analytical Tool Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) therapies are a game changer within cancer therapies and there is a place in history and huge recognition to both Novartis and Kite Pharma (now Gilead Sciences) for being the first companies to b ... Read More

  • Protein Kinase Inhibitors in Oncology: Analytical Tool

    Protein Kinase Inhibitors in Oncology: Analytical Tool Kinase-targeted cancer therapies became really big with imatinib (Gleevec), a landmark drug that has vastly improved the outcomes of patients with chronic myelogenous leukemia. With the human genome encoding 538 protein kinases and many of these ... Read More

  • RNA Therapies in Oncology: Analytical Tool

    RNA Therapies in Oncology: Analytical Tool RNA therapies, such as miRNA, RNAi & siRNA, is an emerging class of biopharmaceutical that has immense potential in cancer medicine. Critical to the field, recent developments in delivery technologies such nanoparticle carriers and conjugation strategies ha ... Read More

  • Bispecific CD3 Molecules in Oncology: Analytical Tool

    Bispecific CD3 Molecules in Oncology: Analytical Tool There is a considerable and robust commercial drug pipeline of T-cell redirecting therapies by bispecific compounds that targets various tumor antigens expressed by malignant cells, and CD3 expressed by the T-cell. Upon binding to both targets, t ... Read More

  • DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool

    DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool DNA Damage Response (DDR) is essential for maintaining the genomic integrity of the cell, and its disruption is one of the hallmarks of cancer. Targeting DDR deficiencies to preferentially kill cancer cells, while minimizing the impact on ... Read More

  • Immune-checkpoint Drugs in Oncology: Analytical Tool

    Immune-checkpoint Drugs in Oncology: Analytical Tool Cancer cells sometimes find ways to avoid being attacked by the immune system. But the event of immune-checkpoint drugs such as nivolumab (Opdivo) and pembrolizumab (Keytruda) have dramatically changed the possibility to harness the power of the i ... Read More

  • Conjugated Antibodies in Oncology: Analytical Tool

    Conjugated Antibodies in Oncology: Analytical Tool The first Antibody-Drug Conjugate (ADC) to receive marketing approval from the US Food and Drug Administration (FDA) was gemtuzumab ozogamicin (Mylotarg) in 2000 which represents a powerful, emerging novel class of anticancer treatment agents that c ... Read More

  • Commercial Interest at ESMO Annual Meeting 2018: Analytical Tool

    Commercial Interest at ESMO Annual Meeting 2018: Analytical Tool The Commercial Interest at ESMO Annual Meeting 2018: Analytical Tool is a must have companion tool for reviewing the direction of commercial drug development emerging from the European Society of Medical Oncology (ESMO 2017) congress. ... Read More

  • Targeting the CD47-SIRPA Axis in Oncology: A Competitive Assessment of Technologies, Dual Targeting, Biomarkers, Combination Therapies & More

    Targeting the CD47-SIRPA Axis in Oncology: A Competitive Assessment of Technologies, Dual Targeting, Biomarkers, Combination Therapies & More Targeting the CD47-SIRPα axis is emerging as one of the most promising new cancer immunotherapy approaches seeking to target innate immune response. This ... Read More

Research Assistance

Live help

Join Alert Me Now!

Sign Up

Find out more on our blog

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings